Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of osteoporosis after acute traumatic spinal cord injury
ACTRN12618000915257Phase 3Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of zoledronic acid in osteoporosis and spinal cord injury (SCI) (3 arms), sponsored by Northern Sydney Local Health District. Primary endpoint: Long-term incidence of fracture. Started Oct 2018; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteoporosisspinal cord injury (SCI)
Beyond the preview
Go deeper on ACTRN12618000915257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000915257.